Identifying SARS-CoV-2 Mutations: A Microarray Multiplex Alternative to Next Generation Sequencing or q-RT-PCR for Rapid COVID-19 Variant Identification


Held Wednesday, June 16, 2021 | 1-2 PM EDT

Sponsored By

Clinical laboratory leaders still face many decisions about the path forward with COVID-19 testing, in light of emerging variants

As multiple SARS-CoV-2 variants emerge globally, it has become imperative to quickly and cost-effectively identify novel variant strains to mitigate their risks. However, while variant identification used to be simple, it is now very complex. Therefore, clinical lab directors, researchers, and public health officials need to know their options—and which are the most efficient, accurate, and cost-effective. Not just for today’s known variants but a technology that can assure ‘future-proof’ for tomorrow’s unknown variants.

On June 16 Dark Daily will host the webinar, Identifying SARS-CoV-2 Mutations: A Microarray Multiplex Alternative to Next Generation Sequencing or q-RT-PCR for Rapid COVID-19 Variant Identification, to bring clinical and public health labs and research institutions up to date on SARS-CoV-2 variant detection and the best options now available for identifying SARS-CoV-2 mutations.

Attend this complimentary webinar to gain a new level of insight into the complexity of variant identification and uncover a more simple, nimble, and cost-effective rapid COVID-19 variant identification solution that:

  • addresses this public health issue, 
  • detects variants the same day, 
  • provides growth for your business, and
  • fits naturally into any clinical lab current COVID-19 lab workflow and at a fraction of the cost and time for alternate methods.

Get expert guidance and actionable takeaways

During this webinar, you will learn how your lab can meet the challenges of efficiently testing for SARS-CoV-2 variants. Expert speakers Michael E. Hogan, PhD, of PathogenDx, and Stephen Young, PhD, of TriCore Reference Laboratories, will explain the challenges of SARS-CoV-2 variant testing via NGS or q-RT-PCR variant assays, and shed new information about the PathogenDx DetectX-Cv Variant assay using a multiplex microarray for Clade Variant Adaptive Surveillance (CVAS). This CVAS technology is supported by the National Institutes of Health (NIH) through the Rapid Acceleration of Diagnostics (RADx) program. 

The webinar explores new high-throughput COVID-19 testing technology that uses a microarray assay to rapidly detect and identify known COVID-19 variants, with a high degree of specificity and sensitivity and within one reaction in about 4 hours. 

Reserve your seat today for this practical, in-depth webinar on Wednesday, June 16, from 1-2:00 PM EDT.

Learning objectives

By attending Identifying SARS-CoV-2 Mutations: A Microarray Multiplex Alternative to Next Generation Sequencing or qRT-PCR for Rapid COVID-19 Variant Identification, you will: 

  • Learn how to accelerate the detection of COVID-19 variants significantly
  • Understand the limits of SARS-CoV-2 RT-qPCR and differences from sequencing 
  • Explore how a single COVID-19 variant test enables on-site detection with same-day results while reducing lab time and costs—adding profitability 
  • Discover the ease of implementation into a lab environment 

This webinar will feature lessons learned and best practices for lab staff and address commonly asked questions about microarray multiplex technology. In addition, you also will have the opportunity to ask questions during the Q&A session. 

Who should attend?

  • Clinical laboratory directors
  • Laboratory managers
  • Clinical pathologists
  • Laboratory technicians
  • Anyone involved in clinical laboratory testing

Your registration includes:

  • The opportunity to pose specific questions and connect directly with speakers during a Q&A session
  • Access to the post-webinar recording

Hosted By


This Webinar at a Glance


Wednesday, June 16, 2021


1 – 2 PM EDT




Your computer and/or speakerphone




Click here or call 512-264-7103

Expert Presenters

Michael E. Hogan, PhD
Chief Scientific Officer
PathogenDx, Inc.
Scottsdale, AZ

Dr. Hogan is Co-founder, Chief Scientific Officer, and a member of the board of directors of PathogenDx. He has invented and commercialized (>30 awarded patents) multiple advanced technologies for biomedical devices, DNA diagnostics, DNA therapy, and ambient temperature biological sample preservation. In academia, Dr. Hogan has held previous faculty appointments in Molecular Biology (Assistant Professor, Princeton University), Molecular Physiology (Professor, Baylor College of Medicine), and Biochemistry (Professor, University of Arizona). He obtained his undergraduate degree from Dartmouth College (Biology), his Ph.D. from Yale University (Molecular Biophysics and Biochemistry), and was a Damon Runyon, Walter Winchell Post-Doctoral Fellow in Cancer at Stanford University.  

Stephen Young, PhD
Director of Research and Clinical Trials
TriCore Reference Laboratories
Albuquerque, NM

Dr. Young has more than three decades of experience in microbiology, with a background in pathology, virology, and infectious diseases. He has active research in the evaluation and development of diagnostic products for clinical microbiology and has completed approximately 100 FDA in vitro diagnostic device trials or market evaluations of diagnostic tests. Dr. Young was a Professor at the University of New Mexico, serving as Director of Clinical Virology and helping in the formation of TriCore Reference Laboratories. He is a long-time Diplomat of the American Board of Medical Microbiology (21 years).